bioAffinity Technologies, Inc. (BIAF) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
BIAF EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BIAF Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 36.1% | -95.6% | -96.6% |
| 2023 | 31.3% | -314.9% | -313.5% |
| 2022 | 90.3% | -83511.5% | -169771.2% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export BIAF earnings history in CSV or JSON format
Free sign-in required to download data
bioAffinity Technologies, Inc. (BIAF) Earnings Overview
As of May 8, 2026, bioAffinity Technologies, Inc. (BIAF) reported trailing twelve-month net income of -$15M, reflecting +17.6% year-over-year growth. The company earned $-13.82 per diluted share over the past four quarters, with a net profit margin of -96.6%.
Looking at the long-term picture, BIAF's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2019.
bioAffinity Technologies, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including LUNG (-$54M net income, -59.7% margin), NVCR (-$173M net income, -20.8% margin), CDNA (-$8M net income, -5.6% margin), BIAF has room to improve margins relative to the peer group. Compare BIAF vs LUNG →
BIAF Earnings vs Peers
Earnings metrics vs comparable public companies
BIAF Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$9M | -13.9% | -$9M | $-22.50 | -96.6% | -95.6% |
| 2023 | -$8M | +2.7% | -$8M | $-27.30 | -313.5% | -314.9% |
| 2022 | -$8M | -28.9% | -$4M | $-54.30 | -169771.2% | -83511.5% |
| 2021 | -$6M | +13.0% | -$2M | $-25.80 | - | - |
| 2020 | -$7M | -119.8% | -$3M | $-29.70 | - | - |
| 2019 | -$3M | - | -$3M | $-13.50 | - | - |
See BIAF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIAF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIAF vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIAF — Frequently Asked Questions
Quick answers to the most common questions about buying BIAF stock.
Is BIAF growing earnings?
BIAF EPS is $-13.82, with earnings growth accelerating to +17.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-15M.
What are BIAF's profit margins?
bioAffinity Technologies, Inc. net margin is -96.6%, with operating margin at -95.6%. Below-average margins reflect competitive or cost pressures.
How consistent are BIAF's earnings?
BIAF earnings data spans 2019-2024. The accelerating earnings trend is +17.6% YoY. Historical data enables comparison across business cycles.